Radar › Screener › VBIO

VBIO

Valion Bio, Inc.
VBIO stock: dilution, delisting risk, reverse split — what the SEC filings say, updated every weekday morning.
Nasdaq · Pharmaceutical Preparations · EDGAR filings (CIK 1787740) · 14 signals · 2 setups · updated Sep 22, 2026

What the filings say Pressure ▼

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.

Radar 85 (high attention) · dilution pressure high · listing risk high · governance risk elevated · runway 1.2 mo · strongest signal: Share count +25% (Jun 30, 2026)

What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

Get tomorrow's read on VBIO — free
One email every weekday morning: what changed across VBIO and ~1,400 other microcaps, every claim linked to the filing.
85Radar · attention score (0–100)
78Dilution pressure · financing + balance sheet
72Listing risk · exchange standards
40Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Forced-raise setup Pressure ▼ strength 0.85

The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (pipe). Base case is a discounted raise; the question is when, not if.

Would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
Would invalidate: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
PIPERunway < 6 months

Listing cliff Pressure ▼ strength 0.80

Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.

Would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
Would invalidate: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Minimum bid deficiencyNear $5M MVLS floorReverse splitRunway < 6 months

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on VBIO
Alerts
One email the morning VBIO files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for VBIO back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 892 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$2.1Mcash + short-term investments as of Jun 30, 2026
1.2 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$4.2Mstockholders' equity as of Jun 30, 2026
$4.0Mpublic float (10-K cover)
22.2Mshares outstanding as of Aug 13, 2026 · was 3.2M May 10, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Sep 3, 2026· 13D amendment Schedule 13D/A filed 2026-09-03 filing 24
Sep 2, 2026· 13D amendment Schedule 13D/A filed 2026-09-02 filing 24
Sep 1, 2026▼ PIPE “pipe” language in 8-K (EX-10.1) filed 2026-09-01 filing 38
Sep 1, 2026▼ Reverse split “reverse split” language in 8-K (EX-10.1) filed 2026-09-01 filing 35
Sep 1, 2026▼ Unregistered sale 8-K Item 3.02 filed 2026-09-01 (accepted 06:00 ET) filing 32
Sep 1, 2026· Officer/director change 8-K Item 5.02 filed 2026-09-01 (accepted 06:00 ET) filing 22
Aug 27, 2026▼ Reverse split “reverse split” language in 8-K (EX-99.1) filed 2026-08-27 filing 40
Aug 27, 2026▼ Minimum bid deficiency “min bid” language in 8-K (8-K) filed 2026-08-27 filing 39
Aug 27, 2026▼ Holder rights modified 8-K Item 3.03 filed 2026-08-27 (accepted 08:30 ET) filing 28
Aug 27, 2026· 13D amendment Schedule 13D/A filed 2026-08-27 filing 24
Aug 24, 2026· 13D amendment Schedule 13D/A filed 2026-08-24 filing 24
Jun 30, 2026▼ Share count +25% Shares outstanding 3,200,824 (2026-05-10) -> 22,189,739 (2026-08-13), +593% filing 46
Jun 30, 2026▼ Runway < 6 months ~1.2 months runway: liquidity $2,108,000 as of 2026-06-30, burn $20,869,889/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing 43
Jun 30, 2026▼ Near $5M MVLS floor Public float $4,000,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing 28

Other forced raise setups

SDST Stardust Power Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · SNTI Senti Biosciences Holdings, · GCTK Glucotrack, Inc. · SOAR Volato Group, Inc. · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans